| 臺大學術典藏 |
2021-02-26T01:59:46Z |
Trends in the susceptibility of commonly encountered clinically significant anaerobes and susceptibilities of blood isolates of anaerobes to 16 antimicrobial agents, including fidaxomicin and rifaximin, 2008–2012, northern Taiwan
|
Wang F.D.; Liao C.H.; Lin Y.T.; WANG-HUEI SHENG; Hsueh P.R. |
| 臺大學術典藏 |
2021-02-26T01:59:31Z |
In?vitro activity of aminoglycosides against clinical isolates of Acinetobacter baumannii complex and other nonfermentative Gram-negative bacilli causing healthcare-associated bloodstream infections in Taiwan
|
Liu J.-Y.;Wang F.-D.;Ho M.-W.;Lee C.-H.;Liu J.-W.;Wang J.-T.;Wang-Huei Sheng;Hseuh P.-R.;Chang S.-C.; Liu J.-Y.; Wang F.-D.; Ho M.-W.; Lee C.-H.; Liu J.-W.; Wang J.-T.; WANG-HUEI SHENG; Hseuh P.-R.; Chang S.-C. |
| 臺大學術典藏 |
2021-02-26T01:59:20Z |
Clinical outcomes and prognostic factors of patients with severe influenza receiving intravenous peramivir salvage therapy in intensive care units
|
Yeh C.-Y.;Wang F.-D.;Chuang Y.-C.;Yang C.-J.;Huang S.-F.;Weng W.-S.;Liaw C.-H.;Wang-Huei Sheng; Yeh C.-Y.; Wang F.-D.; Chuang Y.-C.; Yang C.-J.; Huang S.-F.; Weng W.-S.; Liaw C.-H.; WANG-HUEI SHENG |
| 臺大學術典藏 |
2021-02-26T01:59:15Z |
Nationwide surveillance of antimicrobial resistance among clinically important Gram-negative bacteria, with an emphasis on carbapenems and colistin: Results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2018
|
Lee Y.-L.;Lu M.-C.;Shao P.-L.;Lu P.-L.;Chen Y.-H.;Cheng S.-H.;Ko W.-C.;Lin C.-Y.;Wu T.-S.;Yen M.-Y.;Wang L.-S.;Liu C.-P.;Lee W.-S.;Shi Z.-Y.;Chen Y.-S.;Wang F.-D.;Tseng S.-H.;Lin C.-N.;Chen Y.-H.;Wang-Huei Sheng;Lee C.-M.;Liao M.-H.;Hsueh P.-R.; Lee Y.-L.; Lu M.-C.; Shao P.-L.; Lu P.-L.; Chen Y.-H.; Cheng S.-H.; Ko W.-C.; Lin C.-Y.; Wu T.-S.; Yen M.-Y.; Wang L.-S.; Liu C.-P.; Lee W.-S.; Shi Z.-Y.; Chen Y.-S.; Wang F.-D.; Tseng S.-H.; Lin C.-N.; Chen Y.-H.; WANG-HUEI SHENG; Lee C.-M.; Liao M.-H.; Hsueh P.-R. |
| 臺大學術典藏 |
2021-02-26T01:59:08Z |
National surveillance of antimicrobial susceptibility of bacteremic gram-negative bacteria with emphasis on community-acquired resistant isolates: Report from the 2019 surveillance of multicenter antimicrobial resistance in Taiwan (SMART)
|
Liu P.-Y.; Lee Y.-L.; Lu M.-C.; Shao P.-L.; Lu P.-L.; Chen Y.-H.; Cheng S.-H.; Ko W.-C.; Lin C.-Y.; Wu T.-S.; Yen M.-Y.; Wang L.-S.; Liu C.-P.; Lee W.-S.; Chen Y.-S.; Wang F.-D.; Tseng S.-H.; Lin C.-N.; Tang H.-J.; Chen Y.-H.; WANG-HUEI SHENG; Lee C.-M.; Liao M.-H.; Hsueh P.-R. |
| 國立成功大學 |
2021 |
Antimicrobial susceptibility of bacteremic vancomycin-resistant Enterococcus faecium to eravacycline, omadacycline, lipoglycopeptides, and other comparator antibiotics: Results from the 2019–2020 Nationwide Surveillance of Multicenter Antimicrobial Resist
|
Tsai, H.-Y.;Lee, Y.-L.;Liu, P.-Y.;Lu, M.-C.;Shao, P.-L.;Lu, P.-L.;Cheng, S.-H.;Ko, W.-C.;Lin, C.-Y.;Wu, T.-S.;Yen, M.-Y.;Wang, L.-S.;Liu, C.-P.;Lee, W.-S.;Shi, Z.-Y.;Chen, Y.-S.;Wang, F.-D.;Tseng, S.-H.;Chen, Y.-H.;Sheng, W.-H.;Lee, C.-M.;Chen, Y.-H.;Liao, C.-H.;Hsueh, P.-R. |
| 國立成功大學 |
2021 |
National surveillance of antimicrobial susceptibilities to dalbavancin, telavancin, tedizolid, eravacycline, omadacycline and other comparator antibiotics and serotype distribution of invasive Streptococcus pneumoniae isolates in adults: results from the
|
Chien, Y.-C.;Lee, Y.-L.;Liu, P.-Y.;Lu, M.-C.;Shao, P.-L.;Lu, P.-L.;Cheng, S.-H.;Lin, C.-Y.;Wu, T.-S.;Yen, M.-Y.;Wang, L.-S.;Liu, C.-P.;Lee, W.-S.;Shi, Z.-Y.;Chen, Y.-S.;Wang, F.-D.;Tseng, S.-H.;Chen, Y.-H.;Sheng, W.-H.;Lee, C.-M.;Chen, Y.-H.;Ko, W.-C.;Hsueh, P.-R. |
| 國立成功大學 |
2021 |
In-vitro activity of cefiderocol, cefepime/zidebactam, cefepime/enmetazobactam, omadacycline, eravacycline and other comparative agents against carbapenem-nonsusceptible Enterobacterales: results from the Surveillance of Multicenter Antimicrobial Resistan
|
Lee, Y.-L.;Ko, W.-C.;Lee, W.-S.;Lu, P.-L.;Chen, Y.-H.;Cheng, S.-H.;Lu, M.-C.;Lin, C.-Y.;Wu, T.-S.;Yen, M.-Y.;Wang, L.-S.;Liu, C.-P.;Shao, P.-L.;Shi, Z.-Y.;Chen, Y.-S.;Wang, F.-D.;Tseng, S.-H.;Lin, C.-N.;Chen, Y.-H.;Sheng, W.-H.;Lee, C.-M.;Tang, H.-J.;Hsueh, P.-R. |
| 臺大學術典藏 |
2020-12-29T03:48:03Z |
Clinical outcomes and prognostic factors of patients with severe influenza receiving intravenous peramivir salvage therapy in intensive care units
|
Yeh C.-Y.;Wang F.-D.;Yu-Chung Chuang;Yang C.-J.;Huang S.-F.;Weng W.-S.;Liaw C.-H.;Sheng W.-H.; Yeh C.-Y.; Wang F.-D.; YU-CHUNG CHUANG; Yang C.-J.; Huang S.-F.; Weng W.-S.; Liaw C.-H.; Sheng W.-H. |
| 臺大學術典藏 |
2020-12-18T08:37:40Z |
Trends in the susceptibility of commonly encountered clinically significant anaerobes and susceptibilities of blood isolates of anaerobes to 16 antimicrobial agents, including fidaxomicin and rifaximin, 2008–2012, northern Taiwan
|
Wang F.D.;Liao C.H.;Lin Y.T.;Sheng W.H.;Po-Ren Hsueh; Wang F.D.; Liao C.H.; Lin Y.T.; Sheng W.H.; PO-REN HSUEH |
| 臺大學術典藏 |
2020-12-18T08:37:10Z |
In vitro activity of ceftazidime–avibactam, ceftolozane–tazobactam, and other comparable agents against clinically important Gram-negative bacilli: Results from the 2017 surveillance of multicenter antimicrobial resistance in Taiwan (SMART)
|
Jean S.-S.;Lu M.-C.;Shi Z.-Y.;Tseng S.-H.;Wu T.-S.;Lu P.-L.;Shao P.-L.;Ko W.-C.;Wang F.-D.;Po-Ren Hsueh; Jean S.-S.; Lu M.-C.; Shi Z.-Y.; Tseng S.-H.; Wu T.-S.; Lu P.-L.; Shao P.-L.; Ko W.-C.; Wang F.-D.; PO-REN HSUEH |
| 臺大學術典藏 |
2020-12-18T08:36:57Z |
Nationwide surveillance of antimicrobial resistance among clinically important Gram-negative bacteria, with an emphasis on carbapenems and colistin: Results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2018
|
Chen Y.-H.; Sheng W.-H.; Lee C.-M.; Liao M.-H.; PO-REN HSUEH; Lee Y.-L.;Lu M.-C.;Shao P.-L.;Lu P.-L.;Chen Y.-H.;Cheng S.-H.;Ko W.-C.;Lin C.-Y.;Wu T.-S.;Yen M.-Y.;Wang L.-S.;Liu C.-P.;Lee W.-S.;Shi Z.-Y.;Chen Y.-S.;Wang F.-D.;Tseng S.-H.;Lin C.-N.;Chen Y.-H.;Sheng W.-H.;Lee C.-M.;Liao M.-H.;Po-Ren Hsueh; Lee Y.-L.; Lu M.-C.; Shao P.-L.; Lu P.-L.; Chen Y.-H.; Cheng S.-H.; Ko W.-C.; Lin C.-Y.; Wu T.-S.; Yen M.-Y.; Wang L.-S.; Liu C.-P.; Lee W.-S.; Shi Z.-Y.; Chen Y.-S.; Wang F.-D.; Tseng S.-H.; Lin C.-N. |
| 臺大學術典藏 |
2020-12-18T08:36:52Z |
Activity of ceftolozane-tazobactam against Gram-negative pathogens isolated from lower respiratory tract infections in the Asia-Pacific region: SMART 2015-2016
|
Kuo S.-C.;Liu C.-E.;Lu P.-L.;Chen Y.-S.;Lu M.-C.;Ko W.-C.;Po-Ren Hsueh;Chuang Y.-C.;Wang F.-D.;The Smart Asia-Pacific Group; Kuo S.-C.; Liu C.-E.; Lu P.-L.; Chen Y.-S.; Lu M.-C.; Ko W.-C.; PO-REN HSUEH; Chuang Y.-C.; Wang F.-D.; the SMART Asia-Pacific Group |
| 臺大學術典藏 |
2020-12-18T08:36:44Z |
National surveillance of antimicrobial susceptibility of bacteremic gram-negative bacteria with emphasis on community-acquired resistant isolates: Report from the 2019 surveillance of multicenter antimicrobial resistance in Taiwan (SMART)
|
Wang F.-D.; Wu T.-S.; Yen M.-Y.; Wang L.-S.; Liu C.-P.; Lee W.-S.; Chen Y.-S.; Lin C.-Y.; Ko W.-C.; Cheng S.-H.; Chen Y.-H.; Lu P.-L.; Shao P.-L.; Lu M.-C.; Lee Y.-L.; Liu P.-Y.;Lee Y.-L.;Lu M.-C.;Shao P.-L.;Lu P.-L.;Chen Y.-H.;Cheng S.-H.;Ko W.-C.;Lin C.-Y.;Wu T.-S.;Yen M.-Y.;Wang L.-S.;Liu C.-P.;Lee W.-S.;Chen Y.-S.;Wang F.-D.;Tseng S.-H.;Lin C.-N.;Tang H.-J.;Chen Y.-H.;Sheng W.-H.;Lee C.-M.;Liao M.-H.;Po-Ren Hsueh; Liu P.-Y.; Tseng S.-H.; Lin C.-N.; Tang H.-J.; Chen Y.-H.; Sheng W.-H.; Lee C.-M.; Liao M.-H.; PO-REN HSUEH |
| 臺大學術典藏 |
2020-11-04T09:17:02Z |
Cohort selection for clinical trials using multiple instance learning
|
Dai H.-J.; Wang F.-D.; Chen C.-W.; Su C.-H.; CHI-SHIN WU; Jonnagaddala J. |
| 臺大學術典藏 |
2020-09-29T01:47:32Z |
Are we ready for the global emergence of multidrug-resistant Candida auris in Taiwan?
|
Lu P.-L.; Liu W.-L.; Lo H.-J.; Wang F.-D.; Ko W.-C.; Hsueh P.-R.; Ho M.-W.; Liu C.-E.; Chen Y.-H.; YEE-CHUN CHEN; Chuang Y.-C.; Chang S.-C. |
| 臺大學術典藏 |
2020-06-30T06:13:30Z |
Consensus Statement on the Adherence to Clinical and Laboratory Standards Institute (CLSI) Antimicrobial Susceptibility Testing Guidelines (CLSI-2010 and CLSI-2010-update) for Enterobacteriaceae in Clinical Microbiology Laboratories in Taiwan
|
Hsueh P.-R.;Ko W.-C.;Wu J.-J.;Lu J.-J.;Wang F.-D.;Wu H.-Y.;Wu T.-L.;Lee-Jene Teng; Hsueh P.-R.; Ko W.-C.; Wu J.-J.; Lu J.-J.; Wang F.-D.; Wu H.-Y.; Wu T.-L.; LEE-JENE TENG |
| 臺大學術典藏 |
2020-06-30T06:13:30Z |
Consensus Statement on the Adherence to Clinical and Laboratory Standards Institute (CLSI) Antimicrobial Susceptibility Testing Guidelines (CLSI-2010 and CLSI-2010-update) for Enterobacteriaceae in Clinical Microbiology Laboratories in Taiwan
|
Hsueh P.-R.;Ko W.-C.;Wu J.-J.;Lu J.-J.;Wang F.-D.;Wu H.-Y.;Wu T.-L.;Lee-Jene Teng; Hsueh P.-R.; Ko W.-C.; Wu J.-J.; Lu J.-J.; Wang F.-D.; Wu H.-Y.; Wu T.-L.; LEE-JENE TENG |
| 臺大學術典藏 |
2020-03-27T05:29:51Z |
Consensus Statement on the Adherence to Clinical and Laboratory Standards Institute (CLSI) Antimicrobial Susceptibility Testing Guidelines (CLSI-2010 and CLSI-2010-update) for Enterobacteriaceae in Clinical Microbiology Laboratories in Taiwan
|
Teng L.-J.; Wu T.-L.; Wu H.-Y.; Wang F.-D.; Lu J.-J.; Wu J.-J.; Ko W.-C.; Teng L.-J.;Wu T.-L.;Wu H.-Y.;Wang F.-D.;Lu J.-J.;Wu J.-J.;Ko W.-C.;PO-REN HSUEH; PO-REN HSUEH |
| 臺大學術典藏 |
2020-03-27T05:29:51Z |
Consensus Statement on the Adherence to Clinical and Laboratory Standards Institute (CLSI) Antimicrobial Susceptibility Testing Guidelines (CLSI-2010 and CLSI-2010-update) for Enterobacteriaceae in Clinical Microbiology Laboratories in Taiwan
|
Teng L.-J.; Wu T.-L.; Wu H.-Y.; Wang F.-D.; Lu J.-J.; Wu J.-J.; Ko W.-C.; Teng L.-J.;Wu T.-L.;Wu H.-Y.;Wang F.-D.;Lu J.-J.;Wu J.-J.;Ko W.-C.;PO-REN HSUEH; PO-REN HSUEH |
| 臺大學術典藏 |
2020-03-27T05:29:01Z |
Trends in the susceptibility of commonly encountered clinically significant anaerobes and susceptibilities of blood isolates of anaerobes to 16 antimicrobial agents, including fidaxomicin and rifaximin, 2008–2012, northern Taiwan
|
PO-REN HSUEH;Sheng W.H.;Lin Y.T.;Liao C.H.;Wang F.D.; Wang F.D.; Liao C.H.; Lin Y.T.; Sheng W.H.; PO-REN HSUEH |
| 臺大學術典藏 |
2020-03-27T05:29:01Z |
Trends in the susceptibility of commonly encountered clinically significant anaerobes and susceptibilities of blood isolates of anaerobes to 16 antimicrobial agents, including fidaxomicin and rifaximin, 2008–2012, northern Taiwan
|
PO-REN HSUEH;Sheng W.H.;Lin Y.T.;Liao C.H.;Wang F.D.; Wang F.D.; Liao C.H.; Lin Y.T.; Sheng W.H.; PO-REN HSUEH |
| 臺大學術典藏 |
2020-03-27T05:28:35Z |
In vitro activity of ceftazidime–avibactam, ceftolozane–tazobactam, and other comparable agents against clinically important Gram-negative bacilli: Results from the 2017 surveillance of multicenter antimicrobial resistance in Taiwan (SMART)
|
PO-REN HSUEH;Wang F.-D.;Ko W.-C.;Shao P.-L.;Lu P.-L.;Wu T.-S.;Tseng S.-H.;Shi Z.-Y.;Lu M.-C.;Jean S.-S.; Jean S.-S.; Lu M.-C.; Shi Z.-Y.; Tseng S.-H.; Wu T.-S.; Lu P.-L.; Shao P.-L.; Ko W.-C.; Wang F.-D.; PO-REN HSUEH |
| 臺大學術典藏 |
2020-03-27T05:28:35Z |
In vitro activity of ceftazidime–avibactam, ceftolozane–tazobactam, and other comparable agents against clinically important Gram-negative bacilli: Results from the 2017 surveillance of multicenter antimicrobial resistance in Taiwan (SMART)
|
PO-REN HSUEH;Wang F.-D.;Ko W.-C.;Shao P.-L.;Lu P.-L.;Wu T.-S.;Tseng S.-H.;Shi Z.-Y.;Lu M.-C.;Jean S.-S.; Jean S.-S.; Lu M.-C.; Shi Z.-Y.; Tseng S.-H.; Wu T.-S.; Lu P.-L.; Shao P.-L.; Ko W.-C.; Wang F.-D.; PO-REN HSUEH |
| 臺大學術典藏 |
2020-03-27T05:28:29Z |
Clinical characteristics of patients with bacteraemia due to the emergence of mcr-1-harbouring Enterobacteriaceae in humans and pigs in Taiwan
|
Wang L.-S.; Tseng S.-H.; Lin C.-N.; Chen Y.-H.; Ko W.-C.; Wang F.-D.; PO-REN HSUEH; Infection Control Society of Taiwan; Infection Control Society of Taiwan;PO-REN HSUEH;Wang F.-D.;Ko W.-C.;Chen Y.-H.;Lin C.-N.;Tseng S.-H.;Wang L.-S.;Chen Y.-S.;Shi Z.-Y.;Lu M.-C.;Lin Y.-T.;Lin Y.-T.;Lai C.-C.; Lai C.-C.; Lin Y.-T.; Lin Y.-T.; Lu M.-C.; Shi Z.-Y.; Chen Y.-S. |
